Health News Releases

  • Today February 18
May 11, 2016 11:35
Takeda Reports Results for Fiscal Year 2015 (April 2015 - March 2016) and Forecast for Fiscal Year 2016
FY2015: A year of turnaround to sustained growth; achieved full year management guidance · Underlying revenue up +3.4% (reported revenue growing +1.7% to 1,807.4 billion yen), led by strong performan
May 10, 2016 10:25
Illumina Registers MiSeqDx System in South Korea
Illumina, Inc. (NASDAQ: ILMN) today announced it has received a product approval certificate for the MiSeqDx® Instrument and the MiSeqDx Universal Kit with the Ministry of Food and Drug Safety (MFDS)
May 09, 2016 17:05
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma
Boehringer Ingelheim today announced the enrolment of the first patient in the global Phase III trial evaluating the efficacy and safety of nintedanib in combination with pemetrexed/cisplatin, followe
May 09, 2016 14:10
Takeda Receives $38 Million Grant from the Bill & Melinda Gates Foundation to Support Polio Eradication in Developing Countries
Takeda Pharmaceutical Company Limited (TOKYO:4502), (“Takeda”) today announced a partnership with the Bill & Melinda Gates Foundation to support global polio eradication in developing countries. With
May 04, 2016 17:55
IMS Health and Quintiles to Merge
IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. (NYSE:Q): This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/ho
May 03, 2016 20:50
First-Ever Published Study Proves House Wellness Foods’ Feed LP20® Increases Immunity, Productivity of Whiteleg shrimp [L. vannamei]
A study from Japan has shown for the first time that heat-treated lactobacillus, as found in House Wellness Foods Feed LP20®, is effective in supporting the immune system of the Whiteleg shrimp, rever
April 29, 2016 20:00
Ora® Appoints David Hollander, M.D., M.B.A., as Chief Medical Officer
Ora, Inc., the world’s leading partner for ophthalmic pharmaceutical and device development, announced today the appointment of David A. Hollander, M.D., M.B.A., as Chief Medical Officer and Senior Vi
April 29, 2016 13:00
Phase 3 Trial Results for First Oral Proteasome Inhibitor NINLARO (ixazomib) Published in The New England Journal of Medicine
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that results from the international, randomized, double-blind, placebo-controlled TOURMALINE-MM1 Phase 3 clinical study, evaluating on
April 28, 2016 16:00
Little Life Hack, “Berry” Big Benefit
Women today do it all and don’t have time to be slowed down by pesky infections like urinary tract infections (UTIs). Luckily, there’s a simple solution to stave off that unwelcome sensation, and it’s
April 28, 2016 14:00
Biogen Appoints Michael Ehlers Executive Vice President, Research and Development
Biogen (NASDAQ: BIIB) today announced the appointment of Michael Ehlers, M.D., Ph.D., as executive vice president, Research and Development. Dr. Ehlers will oversee Biogen’s global Research, Drug D
April 27, 2016 09:45
The Revolutionary Intraocular Lens - InFo Instant Focus© - Now Available with an Extended Power Range
The company Swiss Advanced Vision (SAV-IOL SA - www.sav-iol.com) announced the availability of the intraocular lens (IOL) InFo Instant Focus© indicated for the treatment of cataract after removal of t
April 26, 2016 10:45
Quintiles Receives Technology Security Award from IDG’s CSO Magazine for Fourth Consecutive Year
Quintiles, the world’s leading provider of biopharmaceutical services, announced today that it has been named to the 2016 CSO50 by IDG's CSO magazine. This award recognizes the company’s innovative id
April 22, 2016 13:35
One of France’s University Hospitals Adopts Masimo Radical-7®, Including SpHb®, PVI®, and SET® Pulse Oximetry
Masimo (NASDAQ: MASI) announced today that Centre Hospitalier Universitaire (CHU) de Limoges, in Limoges, France has installed Masimo’s Radical-7®, including noninvasive, continuous hemoglobin (SpHb®)
April 20, 2016 19:00
The American Society of Clinical Oncology® Endorses the WIN 2016 Symposium: Innovative Approaches to Improve Cancer Patient Outcomes
The WIN Consortium (WIN) is proud to announce that its symposium dedicated to “Innovative approaches to improve cancer patient outcomes” has been endorsed by the American Society of Clinical Oncology
April 20, 2016 17:15
Herbalife Named as Official Nutrition Sponsor for Vietnamese Athletes Bound for Rio 2016, Commits to New Five-Year Partnership with Vietnam Sports
Herbalife, a global nutrition company (NYSE: HLF), announced today that the Vietnam Olympic Committee (VOC) has named Herbalife Vietnam as the Official Nutrition Sponsor for Vietnamese athletes bound
April 20, 2016 14:15
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced plans to conduct two outcome trials investigating the diabetes medicine Jardiance® (empagliflozin) for the treatment of people
April 15, 2016 19:00
AstraZeneca Presents Positive Tagrisso (osimertinib) Follow-up Data in Lung Cancer at ELCC 2016
AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer
April 14, 2016 10:45
Nominees Announced for 2016-2017 Pioneers in Performance Awards for Latin America
W. L. Gore & Associates, Inc. (Gore) today announced the nominees and opening of voting for the 2016-2017 Pioneers in Performance Awards for Latin America at the Congreso Internacional Cirugia Endovas
April 13, 2016 16:30
Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced NSCLC published in The Lancet Oncology
Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in
April 13, 2016 15:40
Herbalife’s Nutrition At Work Survey Reveals Majority of Asia-Pacific’s Workforce Lead Largely Sedentary Lifestyles, Putting Them at Risk of Obesity
Herbalife, a global nutrition company (NYSE: HLF), today released the findings from the new Nutrition At Work Survey, which revealed that the majority of Asia-Pacific’s workforce lead largely sedentar
April 13, 2016 14:00
Biotech/GM Crops Planted on Two Billion Hectares from 1996 to 2015
Today, the International Service for the Acquisition of Agri-Biotech Applications (ISAAA) released its annual report detailing the adoption of biotech crops, “20th Anniversary of the Global Commercial
April 11, 2016 15:45
Herbalife’s Nutrition At Work Survey Reveals Majority of Asia-Pacific’s Workforce Lead Largely Sedentary Lifestyles, Putting Them at Risk of Obesity
Herbalife, a global nutrition company (NYSE: HLF), today released the findings from the new Nutrition At Work Survey, which revealed that the majority of Asia-Pacific’s workforce lead largely sedentar
April 08, 2016 16:35
The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids
Boehringer Ingelheim today announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not benefit from the addition of
April 07, 2016 16:50
Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung
Boehringer Ingelheim today announced that the European Commission (EC) has granted marketing authorisation for Giotrif® (afatinib) for the treatment of patients with advanced squamous cell carcinoma (
April 04, 2016 16:40
Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations
Boehringer Ingelheim has announced the results of a new interim analysis of data from the ongoing phase III RE-VERSE AD™ patient study that showed a single 5g dose of idarucizumab immediately reversed
25 per page50 per page75 per page100 per page